Intec Pharma (NASDAQ:NTEC) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
This table compares Intec Pharma and Affimed’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
34.9% of Intec Pharma shares are held by institutional investors. Comparatively, 41.1% of Affimed shares are held by institutional investors. 3.3% of Intec Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Intec Pharma and Affimed’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Intec Pharma||N/A||N/A||-$43.54 million||($1.40)||-3.82|
|Affimed||$28.03 million||7.77||-$23.00 million||($0.38)||-9.18|
Affimed has higher revenue and earnings than Intec Pharma. Affimed is trading at a lower price-to-earnings ratio than Intec Pharma, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Intec Pharma has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. Comparatively, Affimed has a beta of 3.23, suggesting that its share price is 223% more volatile than the S&P 500.
This is a summary of current ratings and recommmendations for Intec Pharma and Affimed, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Intec Pharma presently has a consensus target price of $13.30, suggesting a potential upside of 148.60%. Affimed has a consensus target price of $5.23, suggesting a potential upside of 49.97%. Given Intec Pharma’s higher probable upside, equities analysts plainly believe Intec Pharma is more favorable than Affimed.
Affimed beats Intec Pharma on 7 of the 10 factors compared between the two stocks.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa, which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients. It is also developing Accordion Pill Zaleplon that is in a Phase III clinical trial as a treatment for the induction and maintenance of sleep in patients suffering from insomnia; a product candidate, which has completed a Phase I clinical trial for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug induced ulcers; and AP-CBD/THC, AP-THC, and AP-CBD product candidates with Cannabidiol and 9-Tetrahydrocannabinol for the treatment of various indications, including low back pain, neuropathic pain, and fibromyalgia. The company was formerly known as Intec Pharmaceuticals (2000) Ltd. and changed its name to Intec Pharma Ltd. in March 2004. Intec Pharma Ltd. was founded in 2000 and is based in Jerusalem, Israel.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma. The company's products include AFM24, an innate cell-engaging bispecific antibody that treats patients suffering of EGFR expressing solid tumors; AFM26, which binds to B cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its products also comprise AFM11, a T cell TandAb, which is in Phase 1 clinical trial in patients with relapsed CD19+ B cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia (AML); and AMV564, a CD33/CD3-specific T-cell TandAb is in Phase 1 clinical study of refractory AML. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD Anderson's NK-cell product; and Genentech. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.